Sam-A Pharm. Co. Ltd (009300) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sam-A Pharm. Co. Ltd (009300) has a cash flow conversion efficiency ratio of 0.001x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩162.42 Million ≈ $110.07K USD) by net assets (₩228.11 Billion ≈ $154.59 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sam-A Pharm. Co. Ltd - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Sam-A Pharm. Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Sam-A Pharm. Co. Ltd total liabilities for a breakdown of total debt and financial obligations.
Sam-A Pharm. Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sam-A Pharm. Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Passus S.A.
WAR:PAS
|
0.419x |
|
United Palm Oil Industry Public Company Limited
BK:UPOIC
|
0.065x |
|
Innovate Corp
NYSE:VATE
|
-0.092x |
|
GaeaSoft Corp
KQ:051160
|
0.021x |
|
BII Railway Transportation Technology Holdings Company Limited
F:CN6
|
-0.009x |
|
Nexstim Oyj
HE:NXTMH
|
0.099x |
|
Taewoong Logistics Co.Ltd
KQ:124560
|
-0.053x |
|
Davicom Semiconductor Inc
TW:3094
|
0.005x |
Annual Cash Flow Conversion Efficiency for Sam-A Pharm. Co. Ltd (2009–2025)
The table below shows the annual cash flow conversion efficiency of Sam-A Pharm. Co. Ltd from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see Sam-A Pharm. Co. Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩228.11 Billion ≈ $154.59 Million |
₩10.72 Billion ≈ $7.27 Million |
0.047x | -59.04% |
| 2024-12-31 | ₩219.98 Billion ≈ $149.07 Million |
₩25.25 Billion ≈ $17.11 Million |
0.115x | +10.83% |
| 2023-12-31 | ₩200.47 Billion ≈ $135.86 Million |
₩20.76 Billion ≈ $14.07 Million |
0.104x | -4.59% |
| 2022-12-31 | ₩180.62 Billion ≈ $122.40 Million |
₩19.60 Billion ≈ $13.29 Million |
0.109x | +44.26% |
| 2021-12-31 | ₩172.02 Billion ≈ $116.58 Million |
₩12.94 Billion ≈ $8.77 Million |
0.075x | +32.98% |
| 2020-12-31 | ₩166.29 Billion ≈ $112.69 Million |
₩9.41 Billion ≈ $6.38 Million |
0.057x | -28.04% |
| 2019-12-31 | ₩168.15 Billion ≈ $113.95 Million |
₩13.22 Billion ≈ $8.96 Million |
0.079x | -0.82% |
| 2018-12-31 | ₩160.90 Billion ≈ $109.04 Million |
₩12.76 Billion ≈ $8.64 Million |
0.079x | +142.87% |
| 2017-12-31 | ₩156.10 Billion ≈ $105.79 Million |
₩5.10 Billion ≈ $3.45 Million |
0.033x | -53.85% |
| 2016-12-31 | ₩148.92 Billion ≈ $100.92 Million |
₩10.53 Billion ≈ $7.14 Million |
0.071x | -8.33% |
| 2015-12-31 | ₩140.08 Billion ≈ $94.93 Million |
₩10.81 Billion ≈ $7.32 Million |
0.077x | -9.06% |
| 2014-12-31 | ₩134.15 Billion ≈ $90.91 Million |
₩11.38 Billion ≈ $7.71 Million |
0.085x | -26.49% |
| 2012-12-31 | ₩121.33 Billion ≈ $82.22 Million |
₩14.00 Billion ≈ $9.49 Million |
0.115x | +21.89% |
| 2011-12-31 | ₩110.58 Billion ≈ $74.94 Million |
₩10.47 Billion ≈ $7.10 Million |
0.095x | +89.49% |
| 2010-12-31 | ₩101.99 Billion ≈ $69.12 Million |
₩5.10 Billion ≈ $3.45 Million |
0.050x | +147.91% |
| 2009-12-31 | ₩79.92 Billion ≈ $54.16 Million |
₩-8.33 Billion ≈ $-5.65 Million |
-0.104x | -- |
About Sam-A Pharm. Co. Ltd
Sam-A Pharm. Co., Ltd operates as a pharmaceutical company in South Korea. The company offers a range of pharmaceutical products in the areas of respiratory, anti-biotics, anti-virals, anti-histamines, anti-fungals, dermatology, pain/inflammation, gastrointestinal, cardiovascular, metabolism, urological, and steroids, as well as psychotropic agents; and OTC products in the areas of respiratory, a… Read more